Search
for
Sort by
Research
390-420 / 1000+ resultsresearch Sex differences in clinical trials of ALRV5XR treatment of androgenetic alopecia and telogen effluvium
ALRV5XR effectively promotes hair regrowth in both men and women through different mechanisms.
research Safety, tolerability, and PK of topical calcitriol formulation for treatment of chemotherapy-induced alopecia (CIA) in patients receiving taxane-based regimen: Final results.
Topical calcitriol was safe and well-tolerated for potential hair loss prevention in chemotherapy patients.
research 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
research The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trial
Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.
research Impaired Cardiometabolic Effects of Bromocriptine in Men With Early‐Onset Androgenic Alopecia
Men with early-onset hair loss have less cardiometabolic benefit from bromocriptine.
research Дослідження ПРОСПЕКТ IV (ПРОСтамол: ПЕрспективи Комбінованої Терапії) у хворих на доброякісну гіперплазію передміхурової залози
"Flosin – Prostamol Uno" effectively manages BPH symptoms with fewer side effects.
research 15460 Perifollicular pink halo: A potential dermoscopic marker of inflammation in central centrifugal cicatricial alopecia
Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
research 272 Dupilumab treatment in children with alopecia areata: A real-world, single-center observational study
research Med Check
Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
research Reporting on Adverse Clinical Events
Certain medications can reduce mortality risk in COPD patients, but others can increase risks of cardiovascular issues, postoperative delirium, and other adverse effects.
research A phase 1b study of chemo-immunotherapy with pegylated liposomal doxorubicin and Pembrolizumab in estrogen receptor positive metastatic breast cancer
The treatment combination is safe and effective for some patients with this type of breast cancer.
research Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
research 414 A fitst-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and fluorescence contrast in skin cancer
BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.
research CONSULTATIVE, PROACTIVE PHYSICAL THERAPY FOR PEOPLE WITH LUPUS: A CASE REPORT
Proactive physical therapy improved mobility, reduced fatigue, and pain in lupus patients.
research Reporting on Adverse Clinical Events
Different medications can cause serious side effects in some people.
research Oral minoxidil 2.5 mg versus 5 mg for treatment of male androgenetic alopecia: a double-blind randomized clinical trial
The 5 mg dose of oral minoxidil is not more effective than the 2.5 mg dose for treating male hair loss.
research Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study
Topical GT20029 effectively promotes hair regrowth and is well-tolerated.
research A Randomized Controlled Clinical Trial Protocol of Umbilical Cord Mesenchymal Stem Cell‐Derived Small Extracellular Vesicles for the Treatment of Androgenetic Alopecia in Young Males
The trial aims to test a new treatment for hair loss in young men using stem cell-derived vesicles.
research Decision letter for "The Comparative Effects Between Long‐Term and Short‐Term Treatment of Finasteride on Anxiety‐Like and Depression‐Like Behaviors in Early Senescent Male Rats"
research Decision letter for "The Comparative Effects Between Long‐Term and Short‐Term Treatment of Finasteride on Anxiety‐Like and Depression‐Like Behaviors in Early Senescent Male Rats"
research Alopecia in patients treated with molecularly targeted anticancer therapies
Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.
research Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study
GT20029 helps regrow hair in men with hair loss and is well-tolerated.
research Numerical Methods for Decision-Making in Clinical Care: Where to Now?
Hyperbaric oxygen therapy shows promise for multiple sclerosis, but skepticism and funding issues limit tech use in clinics, and outdated single-drug cancer treatments may cause unnecessary side effects.
research P146 A multicentre retrospective study evaluating the real-world efficacy and safety of ritlecitinib in the treatment of alopecia areata
Ritlecitinib shows promise for treating alopecia areata with significant hair regrowth and no serious side effects.
research The global clinical landscape of human-derived extracellular vesicles: an analysis based on ClinicalTrials.gov (2010–2025)
Extracellular vesicles are important for disease treatment and monitoring.
research 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
research Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
The drug combination was safe and showed promise in treating advanced tumors.
research First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.
ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
research Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata
Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.